Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: Lumigan 0.3mg/ml eye drops, solution (2012)

Εκδότης

Εκδότης Allergan Ltd
Διεύθυνση Marlow International, The Parkway, Marlow, Bucks, SL7 1YL, UK
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

LUMIGAN 0.3 mg/ml eye drops, solution.

Qualitative and quantitative composition

One ml of solution contains 0.3 mg bimatoprost. Excipient: One ml of solution contains 0.05 mg benzalkonium ...

Pharmaceutical form

Eye drops, solution. Colourless solution.

Therapeutic indications

Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in ...

Posology and method of administration

Posology The recommended dose is one drop in the affected eye(s) once daily, administered in the evening. ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

Ocular Before treatment is initiated, patients should be informed of the possibility of eyelash growth, ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed. No interactions are anticipated in humans, since systemic ...

Pregnancy and lactation

Pregnancy There are no adequate data from the use of bimatoprost in pregnant women. Animal studies have ...

Effects on ability to drive and use machines

LUMIGAN has negligible influence on the ability to drive and use machines. As with any ocular treatment, ...

Undesirable effects

In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml eye drops, solution. ...

Overdose

No case of overdose has been reported, and is unlikely to occur after ocular administration. If overdose ...

Pharmacodynamic properties

Pharmacotherapeutic group: Ophthalmologicals, prostaglandin analogues ATC code: S01EE03 Mechanism of ...

Pharmacokinetic properties

Absorption Bimatoprost penetrates the human cornea and sclera well in vitro. After ocular administration ...

Preclinical safety data

Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of ...

List of excipients

Benzalkonium chloride Sodium chloride Sodium phosphate dibasic heptahydrate Citric acid monohydrate ...

Incompatibilities

Not applicable.

Shelf life

2 years. 4 weeks after first opening.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

White opaque low density polyethylene bottles with polystyrene screw cap. Each bottle has a fill volume ...

Special precautions for disposal and other handling

No special requirements for disposal.

Marketing authorization holder

Allergan Pharmaceuticals Ireland Castlebar Road Westport Co. Mayo Ireland

Marketing authorization number(s)

EU/1/02/205/001-002

Date of first authorization / renewal of the authorization

8 March 2002 / 20 February 2007

Date of revision of the text

July 2012
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.